Huawei unveils WATCH D3 at ESC Congress
Analysis based on 23 articles · First reported Jul 20, 2026 · Last updated Aug 31, 2026
The launch strengthens Huawei's position in the wearable health technology market, potentially boosting consumer demand for its devices. The CE MDR certification and medical-grade features may enhance Huawei's competitive edge against rivals in Europe, positively impacting its consumer electronics segment.
Huawei showcased its next-generation ambulatory blood pressure monitor, the HUAWEI WATCH D3, at the European Society of Endocrinology Congress (ESC Congress 2026) in Munich, Germany, on August 31, 2026. The device, which received CE MDR certification in the European Union, is set for official launch at Huawei's 'Chase the Wild' Innovative Product Launch in Munich on September 2, 2026. The WATCH D3 builds on Huawei's decade-long development in wearable health monitoring, offering accurate blood pressure measurement at elevated heart rates, pre- and post-exercise tracking, and reminders for high-altitude and temperature-change scenarios. The event also previewed other products including the HUAWEI WATCH GT 7 Series, HUAWEI WATCH 6 Series, MatePad Pro 12-inch, FreeBuds Neo, and nova 16s series.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard